Triple-Negative Breast Cancer: Expert Perspectives On Recent Advances

EP. 1: Standard of Care for Early-Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 2: Role of pCR in Early Stage TNBC Management

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 3: Key Trials in ICI-Based Therapy for Early Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 4: Early Stage TNBC: Phase 3 IMpassion031 Study

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 5: Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 6: ICI-Based Therapy in TNBC: Immune-Related Adverse Events

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 7: Emerging Data on Biomarkers in ES TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 8: Current Trials for Treatment of Early Stage TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 9: Standard of Care for Metastatic TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 10: KEYNOTE-355 Trial in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 11: Testing for PD-L1 Expression in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 12: Standard of Care for BRCA+ mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 13: Sequencing Therapies for mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 14: Phase 3 ASCENT Trial in mTNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 15: Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

EP. 16: Future Directions for Treatment of TNBC

ByJoyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center,Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute,Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center,Kevin M. Kalinsky, MD, Columbia University Medical Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University

October 23rd 2020

Episodes

EP. 1: Standard of Care for Early-Stage TNBC

EP. 2: Role of pCR in Early Stage TNBC Management

EP. 3: Key Trials in ICI-Based Therapy for Early Stage TNBC

EP. 4: Early Stage TNBC: Phase 3 IMpassion031 Study

EP. 5: Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC

EP. 6: ICI-Based Therapy in TNBC: Immune-Related Adverse Events

EP. 7: Emerging Data on Biomarkers in ES TNBC

EP. 8: Current Trials for Treatment of Early Stage TNBC

EP. 9: Standard of Care for Metastatic TNBC

EP. 10: KEYNOTE-355 Trial in mTNBC

EP. 11: Testing for PD-L1 Expression in mTNBC

EP. 12: Standard of Care for BRCA+ mTNBC

EP. 13: Sequencing Therapies for mTNBC

EP. 14: Phase 3 ASCENT Trial in mTNBC

EP. 15: Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

EP. 16: Future Directions for Treatment of TNBC

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

The OncFive: Top Oncology Articles for the Week of 8/16

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC